PT  - JOURNAL ARTICLE
AU  - Desai, Kanan T.
AU  - Alfaro, Karla
AU  - Mendoza, Laura
AU  - Faron, Matthew
AU  - Mesich, Brian
AU  - Maza, Mauricio
AU  - Dominguez, Rhina
AU  - Valenzuela, Adriana
AU  - DÍaz Acosta, Chyntia
AU  - MartÍnez, Magaly
AU  - Felix, Juan C.
AU  - Masch, Rachel
AU  - Gabrilovich, Sofia
AU  - Plump, Michael
AU  - Novetsky, Akiva P.
AU  - Einstein, Mark H.
AU  - Douglas, Nataki C.
AU  - Cremer, Miriam
AU  - Wentzensen, Nicolas
TI  - Multi-site clinical validation of Isothermal Amplification based SARS-COV-2 detection assays using different sampling strategies
AID  - 10.1101/2021.07.01.21259879
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.01.21259879
4099  - http://medrxiv.org/content/early/2021/07/06/2021.07.01.21259879.short
4100  - http://medrxiv.org/content/early/2021/07/06/2021.07.01.21259879.full
AB  - Background Isothermal amplification-based tests were developed as rapid, low-cost, and simple alternatives to real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-COV-2 detection.Methods Clinical performance of two isothermal amplification-based tests (Atila Biosystems iAMP COVID-19 detection test and OptiGene COVID-19 Direct Plus RT-LAMP test) was compared to clinical RT-PCR assays using different sampling strategies. A total of 1378 participants were tested across four study sites.Results Compared to standard of care RT-PCR testing, the overall sensitivity and specificity of the Atila iAMP test for detection of SARS-CoV-2 were 76.2% and 94.9%, respectively, and increased to 88.8% and 89.5%, respectively, after exclusion of an outlier study site. Sensitivity varied based on the anatomic collected site. Sensitivity for nasopharyngeal was 65.4% (range across study sites:52.8%-79.8%), mid-turbinate 88.2%, saliva 55.1% (range across study sites:42.9%-77.8%) and anterior nares 66.7% (range across study sites:63.6%-76.5%). The specificity for these anatomic collection sites ranged from 96.7% to 100%. Sensitivity improved in symptomatic patients (overall 82.7%) and those with a higher viral load (overall 92.4% for ct≤25). Sensitivity and specificity of the OptiGene Direct Plus RT-LAMP test, conducted at a single study-site, were 25.5% and 100%, respectively.Conclusions The Atila iAMP COVID test with mid-turbinate sampling is a rapid, low-cost assay for detecting SARS-COV-2, especially in symptomatic patients and those with a high viral load, and could be used to reduce the risk of SARS-COV-2 transmission in clinical settings. Variation of performance between study sites highlights the need for site-specific clinical validation of these assays before clinical adoption.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThe research was funded by the intramural NCI Cancer MoonshotSM and intramural research program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical review board of Comite Nacional de Etica de Investigacion en Salud (IRB no FWA00010986) in El Salvador, Comite de Etica, Instituto de Investigaciones en Ciencias de la Salud, Universida Nacional de Asucion (IRB no P37 2020) in Paraguay, MCW IRB (IRB no FWA00000820) in Wisconsin, and the Newark Health Sciences IRB for Rutgers Biomedical Health Sciences (IRB no. Pro2020001801) in New Jersey.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used in the current study are available from the corresponding author on reasonable request.CIConfidence IntervalCOVID-19Coronavirus Disease of 2019CTCycle ThresholdEUAEmergency Use AuthorizationiAMPIsothermal AmplificationIFUInstruction for UseLAMPLoop-mediated Isothermal AmplificationLMICLow- and Middle-Income CountriesLODLimit of DetectionMCWMedical College of WisconsinNAATNucleic Acid Amplification TestNPNasopharyngealOPOropharyngealNJMSRutgers New Jersey Medical SchoolRT-PCRReverse Transcription-Polymerase Chain ReactionSARS-COV-2Severe Acute Respiratory Syndrome Coronavirus 2SPSSStatistical Package of Social StudiesVTMViral Transport Medium